

Research Article

Preliminary ^{19}F -MRS Study of Tumor Cell Proliferation with 3'-deoxy-3'-fluorothymidine and Its Metabolite (FLT-MP)

In Ok Ko,^{1,2} Ki-Hye Jung,¹ Mi Hyun Kim,¹ Kyeong Jun Kang,¹
Kyo Chul Lee,¹ Kyeong Min Kim,³ Insup Noh,⁴ Yong Jin Lee,¹ Sang Moo Lim,⁵
Jung Young Kim,¹ and Ji-Ae Park¹

¹Division of RI-Convergence Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

²Convergence Institute of Biomedical Engineering and Biomaterials, Seoul National University of Science & Technology, Seoul, Republic of Korea

³Division of Medical Radiation Equipment, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

⁴Department of Chemical & Biomolecular Engineering, Seoul National University of Science & Technology, Seoul, Republic of Korea

⁵Department of Nuclear Medicine, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

Correspondence should be addressed to Jung Young Kim; jykim@kirams.re.kr and Ji-Ae Park; jpark@kirams.re.kr

Received 11 May 2017; Accepted 17 July 2017; Published 26 September 2017

Academic Editor: Giancarlo Pascali

Copyright © 2017 In Ok Ko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The thymidine analogue 3'-deoxy-3'-[^{18}F]fluorothymidine, or [^{18}F]fluorothymidine ([^{18}F]FLT), is used to measure tumor cell proliferation with positron emission tomography (PET) imaging technology in nuclear medicine. FLT is phosphorylated by thymidine kinase I (TKI) and then trapped inside cells; it is not incorporated into DNA. Imaging with ^{18}F -radiolabeled FLT is a noninvasive technique to visualize cellular proliferation in tumors. However, it is difficult to distinguish between [^{18}F]FLT and its metabolites by PET imaging, and quantification has not been attempted using current imaging methods. In this study, we successfully acquired *in vivo* ^{19}F spectra of natural or nonradioactive 3'-deoxy-3'-fluorothymidine ([^{19}F]FLT) and its monophosphate metabolite (FLT-MP) in a tumor xenograft mouse model using 9.4T magnetic resonance imaging (MRI). This preliminary result demonstrates that ^{19}F magnetic resonance spectroscopy (MRS) with FLT is suitable for the *in vivo* assessment of tumor aggressiveness and for early prediction of treatment response.

1. Introduction

Tumor cell proliferation is a useful prognostic indicator of tumor aggressiveness, and proliferation may be evaluated to monitor and predict the response to antitumor therapy. Tumor cells and tissues with a high proliferation rate require a high rate of DNA synthesis [1–5]. Radiolabeled thymidine analogues are standard biomarkers for DNA synthesis and are generally used in nuclear medicine. One thymidine analogue, [^{11}C]-labeled thymidine, is well known as a radiotracer for positron emission tomography (PET) studies of tumor cell proliferation and DNA synthesis [6–9]. However, the short physical half-life (20 min) of [^{11}C]-thymidine and its rapid biodegradation are practical limitations to its use

[4, 10]. Consequently, the use of [^{18}F]-labeled 3'-deoxy-3'-fluorothymidine ([^{18}F]FLT) PET imaging to assess proliferation in various tumors has been reported in preclinical and clinical studies [11–13]. [^{18}F]FLT in the cell is phosphorylated by the enzyme thymidine kinase I (TKI), producing [^{18}F]FLT monophosphate ([^{18}F]FLT-MP). [^{18}F]FLT-MP can then be sequentially phosphorylated to form [^{18}F]FLT diphosphate ([^{18}F]FLT-DP) and [^{18}F]FLT triphosphate ([^{18}F]FLT-TP), which are metabolically trapped inside cells and are not incorporated into DNA (Figure 1) [14]. Li et al. demonstrated that metabolites of intracellular FLT during *in vitro* cell growth could be accurately measured with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay [15]. However, this technique is considered a restrictive




FIGURE 2: Typical coil-localized ^{19}F spectra of (a) FLT and (b) FLT-MP containing TFA as a reference. (c) ^{19}F MR images of phantoms containing 25, 50, 100, and 200 mM FLT. (d) Signal intensity in ^{19}F MR images of FLT phantoms, as a function of FLT concentration ($R^2 = 0.998$). (e) Typical coil-localized ^{19}F spectrum of a phantom containing a mixture of FLT (100 mM) and FLT-MP (60 mM). (f) ^{19}F MRS spectrum of a phantom containing a mixture of FLT (100 mM) and FLT-MP (60 mM). The area ratio of FLT (100 mM) to FLT-MP (60 mM) is approximately 100 to 60.

phantom study, this signal represented FLT-MP despite being very weak.

Experimentally speaking, it was very difficult to accurately perform chemical shift imaging (CSI) of FLT and FLT-MP. Our studies, however, first detected a remarkable ^{19}F MR signal in the tumors of living mice, thereby observing the metabolism of FLT by ^{19}F MRS *in vivo*. Understanding the metabolism of FLT in a tumor-bearing mouse model may help us associate metabolism with PET data from [^{18}F]FLT, a commonly used radiopharmaceutical in nuclear medicine; [^{18}F]FLT is a good tracer of cell proliferation for assessment of tumor aggressiveness and early prediction of treatment response [12]. PET technology, high sensitivity, and the radiation of positron-emitting radioisotopes can easily permeate tissues, making PET a powerful molecular imaging modality to monitor the progression of cancer [22]. However,

PET alone cannot readily distinguish between [^{18}F]FLT and [^{18}F]FLT-MP. Specifically, it is very difficult to simultaneously identify metabolites *in vivo* by kinetic analysis of FLT-PET images [8]. In that respect, our results show that ^{19}F MRS is a noninvasive and practical way to identify biomolecules *in vivo*, including fluorine atoms; it may, thus, be utilized to complement other imaging tools, such as PET.

MRI/MRS is also a promising molecular imaging method for cancer theragnostics [23, 24]. For example, ^{13}C MRI/MRS study of hyperpolarized [^{13}C]pyruvate and its metabolite ([^{13}C]lactate) could be recently used to measure early responses to therapy, and the utilization of metabolite levels has been studied in clinical practice [25–27]. The hyperpolarized ^{13}C compounds, however, have restriction on the metabolism studies of DNA synthesis due to a time limit of hyperpolarization. The results of the present study, though




FIGURE 3: ^{19}F NMR spectra of MCF-7 cell suspensions treated with FLT ($0.1 \text{ mg}/1 \times 10^7$ cells) as a function of time (d–g). The quantification in a relative ratio of FLT to FLT-MP was indicated. Typical spectra of (a) FLT (-175.4 ppm), (b) FLT-MP (-174.4 ppm), and (c) MCF-7 cells without FLT addition.

preliminary, demonstrate that detection of [^{19}F]FLT and its metabolite using ^{19}F MRS might provide a novel avenue for cancer theragnostics.

3. Conclusion

In this study, FLT and its metabolite were measured for the first time in an *in vivo* mouse model using ^{19}F MRS. This result showed that ^{19}F MRS is suitable for the purpose of *in vivo* monitoring of specific drugs including radiopharmaceuticals and their metabolites. In addition, the findings of this study may support the clinical use of ^{19}F MRI/MRS for the quantification and monitoring of the cellular proliferation in cancer and to assess the effectiveness of responses to therapy. Further studies are needed to improve the ^{19}F MRS and CSI techniques for *in vivo* detection.

4. Materials and Methods

4.1. Chemicals. All reagents were purchased from commercial sources, and the following agents were FLT and FLT-MP (Research Center FutureChem Co., Ltd., Seoul, Korea) and trifluoroacetic acid (TFA) (Sigma-Aldrich, St. Louis, MO).

4.2. High-Performance Liquid Chromatography (HPLC). The locations of compound were confirmed by analytical HPLC

using an Atlantis C_{18} analytical column ($5 \mu\text{m}$, $3.0 \times 150 \text{ mm}$) with 10% EtOH in water (v/v) as the mobile phase at a flow rate of $0.4 \text{ mL}/\text{min}$. The retention times (R_t) for FLT and FLT-MP were 7.1 min and 2 min , respectively.

4.3. Cell Culture. The MCF-7 human breast cancer cell line expressing the HSV-tk gene was maintained in RPMI-1640 medium supplemented with 10% FBS, 1% antibiotics, and $100 \mu\text{g}/\text{mL}$ of G418 (Invitrogen). Cultures were maintained in a 37°C incubator with 5% CO_2 , and the medium was changed every 3 days.

For ^{19}F MRS, MCF-7 cells were plated, and 5×10^7 cells were suspended in $500 \mu\text{L}$ of serum-free RPMI medium containing FLT (16.7 mM) before being incubated at 37°C for different time periods (5 min, 30 min, 60 min, and 120 min). The cells were divided into two groups. The first group of cells was not washed and was used for ^{19}F NMR and ^{19}F MRS. The second group of cells was washed three times with PBS, scraped from the plate, centrifuged at $1,000 \text{ rpm}$ for 3 min, and then collected for use in ^{19}F NMR, ^{19}F MRS, and HPLC analyses.

For HPLC, the pellets were resuspended in PBS to a final volume of 1 mL and were then lysed by three cycles of freezing and thawing; the lysates were centrifuged at $14,000 \text{ rpm}$ for 5 min at 4°C . The supernatant was used for HPLC analysis.

FLT and FLT-MP were extracted from the samples after growth for 5 min, 30 min, 60 min, or 120 min by three cycles




FIGURE 4: HPLC chromatograms of (a) FLT (Rt, 7.1 min), (b) FLT-MP (Rt, 2.0 min), and (c) MCF-7 cells treated with FLT.

of freezing and thawing. After centrifugation (14,000 rpm for 5 min at 4°C), the samples comprising a 90:10 mixture of supernatant: D₂O, were placed in 5 mm nuclear magnetic resonance (NMR) tubes for data acquisition.

4.4. NMR. The ¹⁹F NMR measurements were conducted at 28°C on a Bruker 400-MHz NMR spectrometer, equipped with a 5-mm BBFO probe. The experimental parameters were as follows: pulse angle, 90° (18.32 μsec); repetition rate, 1 sec; 172 K data set; 2,000 scans. All ¹⁹F data were processed using TopSpin and analyzed with MestReNova.

4.5. Animals. All animal experiments were conducted in compliance with the Guidelines for the Care and Use of Research Animals under protocols approved by the Korea Institute of Radiological and Medical Sciences (KIRAMS) Animal Studies Committee.

MCF-7 tumor cells (10⁶ cells/mL) suspended in RPMI serum-depletion media were inoculated into the subcutaneous tissue (sc) of female BALB/c nude mice (6 weeks, 20–25 g of body mass). The mice were anesthetized with 1.5%

isoflurane. To monitor the formation of FLT-MP, ¹H MRI and ¹⁹F MRS were performed after intravenous bolus injections of FLT (200 mM, 100 μL).

4.6. MRI. All ¹H MRI and ¹⁹F MRI/MRS data were acquired with a 9.4T animal MRI system and 20 mm surface coil (370–420 MHz) (Agilent Technologies, USA).

¹H MR images were acquired with a fast spin echo sequence using the following settings: repetition time (TR) 2500 ms, echo time (TE) 25 ms, matrix 256 × 256, field of view (FOV) 5 × 5 cm², slice thickness 2 mm, gap 0 mm, averages 2, and scan time 2 min 45 sec.

¹⁹F MR images of phantom were acquired with a gradient echo sequence using the following settings: TR 100 ms, TE 4.0 ms, matrix 64 × 64, FOV 5 × 5 cm², slice thickness 2 mm, gap 0 mm, averages 1200, and scan time 2 h 8 min.

¹⁹F MRS of phantoms and in vivo data were acquired with Point-Resolved Spectroscopy (PRESS) using the following settings: TR 3000 ms, TE 15 ms, voxel size 5 × 5 × 5 mm³, averages 512, and scan time 25 min.




FIGURE 5: *In vivo* ^{19}F MR spectrum in a mouse tumor model. FLT (200 mM, 100 μL) was injected into tail veins. (a) Anatomical ^1H MR images of the mouse were obtained using fast spin echo sequence with the voxel of interest in the tumor ($5 \times 5 \times 5 \text{ mm}^3$). Time-course of ^{19}F MR spectra at (b) 25 min after injection (a.i.) (-175.9 ppm) and (c) 90 min a.i. (-175.08 ppm). ^{19}F MRS data were acquired with Point-RESolved Spectroscopy (PRESS) using TR 3000 ms, TE 15 ms, averages 512, scan time 25 min.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This research was supported by a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (no. 1711045539;171104541/50461-2017).

References

- [1] J. L. Schwartz, Y. Tamura, R. Jordan, J. R. Grierson, and K. A. Krohn, "Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs," *Journal of Nuclear Medicine*, vol. 44, pp. 2027–2032, 2003.
- [2] J. R. Bading and A. F. Shields, "Imaging of cell proliferation: status and prospects," *Journal of Nuclear Medicine*, vol. 49, supplement 2, pp. 64S–80S, 2008.
- [3] V. W. Hu, G. E. Black, A. Torres-Duarte, and F. P. Abramson, " ^3H -thymidine is a defective tool with which to measure rates of DNA synthesis," *The FASEB journal: official publication of the Federation of American Societies for Experimental Biology*, vol. 16, no. 11, pp. 1456–1457, 2002.
- [4] S. Nimmagadda and A. F. Shields, "The role of DNA synthesis imaging in cancer in the era of targeted therapeutics," *Cancer and Metastasis Reviews*, vol. 27, no. 4, pp. 575–587, 2008.
- [5] L. M. Kenny, E. O. Aboagye, and P. M. Price, "Positron emission tomography imaging of cell proliferation in oncology," *Clinical Oncology*, vol. 16, no. 3, pp. 176–185, 2004.
- [6] D. Christman, E. J. Crawford, M. Friedkin, and A. P. Wolf, "Detection of DNA Synthesis in Intact Organisms with Positron-Emitting [^3H]Thymidine," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 69, no. 4, pp. 988–992, 1972.
- [7] T. Tahara, Z. Zhang, M. Ohno et al., "A novel ^{11}C -labeled thymidine analog, [^{11}C]AZT, for tumor imaging by positron emission tomography," *EJNMMI Research*, vol. 5, 124, no. 1, 2015.
- [8] D. A. Mankoff, A. F. Shields, J. M. Link et al., "Kinetic analysis of 2- ^{11}C thymidine PET imaging studies: Validation studies," *Journal of Nuclear Medicine*, vol. 40, no. 4, pp. 614–624, 1999.
- [9] J. Toyohara, M. Okada, C. Toramatsu, K. Suzuki, and T. Irie, "Feasibility studies of 4'-[methyl- ^{11}C]thiothymidine as a tumor

- proliferation imaging agent in mice,” *Nuclear Medicine and Biology*, vol. 35, no. 1, pp. 67–74, 2008.
- [10] D. A. Mankoff, A. F. Shields, M. M. Graham, J. M. Link, J. F. Eary, and K. A. Krohn, “Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis,” *Journal of Nuclear Medicine*, vol. 39, no. 6, pp. 1043–1055, 1998.
- [11] A. F. Shields, “PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls,” *The Journal of Nuclear Medicine*, vol. 44, no. 9, pp. 1432–1434, 2003.
- [12] W. Chen, T. Cloughesy, N. Kamdar et al., “Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG,” *Journal of Nuclear Medicine*, vol. 46, no. 6, pp. 945–952, 2005.
- [13] A. F. Shields, J. R. Grierson, B. M. Dohmen et al., “Imaging proliferation in vivo with [F-18]FLT and positron emission tomography,” *Nature Medicine*, vol. 4, no. 11, pp. 1334–1336, 1998.
- [14] E. T. McKinley, G. D. Ayers, R. A. Smith et al., “Limits of [18F]-FLT PET as a Biomarker of Proliferation in Oncology,” *PLoS ONE*, vol. 8, no. 3, Article ID e58938, 2013.
- [15] W. Li, M. Araya, M. Elliott et al., “Monitoring cellular accumulation of 3-deoxy-3-fluorothymidine (FLT) and its monophosphate metabolite (FLT-MP) by LC-MS/MS as a measure of cell proliferation in vitro,” *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 879, no. 28, pp. 2963–2970, 2011.
- [16] J. Ruiz-Cabello, B. P. Barnett, P. A. Bottomley, and J. W. M. Bulte, “Fluorine (¹⁹F) MRS and MRI in biomedicine,” *NMR in Biomedicine*, vol. 24, no. 2, pp. 114–129, 2011.
- [17] R. B. van Heeswijk, Y. Pilloud, U. Flögel, J. Schwitter, and M. Stuber, “Fluorine-19 magnetic resonance angiography of the mouse,” *PLoS ONE*, vol. 7, no. 7, Article ID e42236, 2012.
- [18] I. Tirotta, V. Dichiarante, C. Pigliacelli et al., “(19)F magnetic resonance imaging (MRI): from design of materials to clinical applications,” *Chemical Reviews*, vol. 115, no. 2, pp. 1106–1129, 2015.
- [19] X. Yue, Z. Wang, L. Zhu et al., “Novel ¹⁹F activatable probe for the detection of matrix metalloprotease-2 activity by MRI/MRS,” *Molecular Pharmaceutics*, vol. 11, no. 11, pp. 4208–4217, 2014.
- [20] C. Gonzales, H. A. I. Yoshihara, N. Dilek et al., “In-vivo detection and tracking of T cells in various organs in a melanoma tumor model by ¹⁹F-fluorine MRS/MRI,” *PLoS ONE*, vol. 11, no. 10, Article ID e0164557, 2016.
- [21] W. Yu, Y. Yang, S. Bo et al., “Design and Synthesis of Fluorinated Dendrimers for Sensitive ¹⁹F MRI,” *Journal of Organic Chemistry*, vol. 80, no. 9, pp. 4443–4449, 2015.
- [22] K. A. Krohn, D. A. Mankoff, and J. F. Eary, “Imaging cellular proliferation as a measure of response to therapy,” *Journal of Clinical Pharmacology*, vol. 41, (suppl), pp. 96S–103S, 2001.
- [23] P. Caravan, “Strategies for increasing the sensitivity of gadolinium based MRI contrast agents,” *Chemical Society Reviews*, vol. 35, no. 6, pp. 512–523, 2006.
- [24] W. Negendank, “Studies of human tumors by MRS: A review,” *NMR in Biomedicine*, vol. 5, no. 5, pp. 303–324, 1992.
- [25] M. J. Albers, R. Bok, A. P. Chen et al., “Hyperpolarized ¹³C lactate, pyruvate, and alanine: Noninvasive biomarkers for prostate cancer detection and grading,” *Cancer Research*, vol. 68, no. 20, pp. 8607–8615, 2008.
- [26] J. D. MacKenzie, Y.-F. Yen, D. Mayer, J. S. Tropp, R. E. Hurd, and D. M. Spielman, “Detection of inflammatory arthritis by using hyperpolarized ¹³C-pyruvate with MR imaging and spectroscopy,” *Radiology*, vol. 259, no. 2, pp. 414–420, 2011.
- [27] K. R. Keshari and D. M. Wilson, “Chemistry and biochemistry of ¹³C hyperpolarized magnetic resonance using dynamic nuclear polarization,” *Chemical Society Reviews*, vol. 43, no. 5, pp. 1627–1659, 2014.